Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1533 ARTÍCULOS , VIENDO DEL 1126 AL 1140

Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Disease Biomarkers: A Pilot Clinical Trial

Craft S, Claxton A, Baker LD, Hanson AJ, Cholerton B, Trittschuh EH, Dahl D, Caulder E, Neth B, Montine TJ, Jung Y, Maldjian J, Whitlow C, Friedman S.

J Alzheimers Dis. 2017;57(4):1325-1334. doi: 10.3233/JAD-161256.

Role of LRP1 in the pathogenesis of Alzheimer's disease: evidence from clinical and preclinical studies

Shinohara M, Tachibana M, Kanekiyo T, Bu G.

J Lipid Res. 2017 Jul;58(7):1267-1281. doi: 10.1194/jlr.R075796. Epub 2017 Apr 4.

A phase 3 trial of IV immunoglobulin for Alzheimer disease

Relkin NR, Thomas RG, Rissman RA, Brewer JB, Rafii MS, van Dyck CH, Jack CR, Sano M, Knopman DS, Raman R, Szabo P, Gelmont DM, Fritsch S, Aisen PS; Alzheimer's Disease Cooperative Study.

Neurology. 2017 May 2;88(18):1768-1775. doi: 10.1212/WNL.0000000000003904. Epub 2017 Apr 5.

Neuropsychiatric Symptoms and Neuroimaging Biomarkers in Alzheimer Disease: "Which is the Cart and Which is the Horse?"

Geda YE, Krell-Roesch J, Sambuchi N, Michel BF.

Am J Geriatr Psychiatry. 2017 Jul;25(7):694-696. doi: 10.1016/j.jagp.2017.03.007. Epub 2017 Mar 16.

Aβ levels in the jugular vein and high molecular weight Aβ oligomer levels in CSF can be used as biomarkers to indicate the anti-amyloid effect of IVIg for Alzheimer's disease

Kasai T, Kondo M, Ishii R, Tanaka A, Ataka S, Shimada H, Tomiyama T, Mori H, Taylor M, Allsop D, Nakagawa M, Mizuno T, Tokuda T.

PLoS One. 2017 Apr 10;12(4):e0174630. doi: 10.1371/journal.pone.0174630. eCollection 2017.

[Correlation between Alzheimer disease and cataract]

Liu SS, Zhu SQ.

Zhonghua Yan Ke Za Zhi. 2017 Apr 11;53(4):314-316. doi: 10.3760/cma.j.issn.0412-4081.2017.04.016.

How the cognitive reserve interacts with β-amyloid deposition in mitigating FDG metabolism: An observational study

Carapelle E, Serra L, Modoni S, Falcone M, Caltagirone C, Bozzali M, Specchio LM, Avolio C.

Medicine (Baltimore). 2017 Apr;96(16):e5876. doi: 10.1097/MD.0000000000005876.

Applying fluid biomarkers to Alzheimer's disease

Zetterberg H.

Am J Physiol Cell Physiol. 2017 Jul 1;313(1):C3-C10. doi: 10.1152/ajpcell.00007.2017. Epub 2017 Apr 19.

Elucidating the Role of TREM2 in Alzheimer's Disease

Ulrich JD, Ulland TK, Colonna M, Holtzman DM.

Neuron. 2017 Apr 19;94(2):237-248. doi: 10.1016/j.neuron.2017.02.042.

Biomarkers for Early Diagnosis of Alzheimer's Disease in the Oldest Old: Yes or No?

Paolacci L, Giannandrea D, Mecocci P, Parnetti L.

J Alzheimers Dis. 2017;58(2):323-335. doi: 10.3233/JAD-161127.

The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer's pathology

Westwood S, Liu B, Baird AL, Anand S, Nevado-Holgado AJ, Newby D, Pikkarainen M, Hallikainen M, Kuusisto J, Streffer JR, Novak G, Blennow K, Andreasson U, Zetterberg H, Smith U, Laakso M, Soininen H, Lovestone S.

Alzheimers Res Ther. 2017 Apr 26;9(1):31. doi: 10.1186/s13195-017-0258-6.

Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database

Ben Bouallègue F, Mariano-Goulart D, Payoux P; Alzheimer’s Disease Neuroimaging Initiative (ADNI).

Alzheimers Res Ther. 2017 Apr 26;9(1):32. doi: 10.1186/s13195-017-0260-z.

APOE ε4 allele elevates the expressions of inflammatory factors and promotes Alzheimer's disease progression: A comparative study based on Han and She populations in the Wenzhou area

Fan YY, Cai QL, Gao ZY, Lin X, Huang Q, Tang W, Liu JH.

Brain Res Bull. 2017 Jun;132:39-43. doi: 10.1016/j.brainresbull.2017.04.017. Epub 2017 Apr 29.

N-glycan and Alzheimer's disease

Kizuka Y, Kitazume S, Taniguchi N.

Biochim Biophys Acta Gen Subj. 2017 Oct;1861(10):2447-2454. doi: 10.1016/j.bbagen.2017.04.012. Epub 2017 Apr 29.

Bryostatin Effects on Cognitive Function and PKCɛ in Alzheimer's Disease Phase IIa and Expanded Access Trials

Nelson TJ, Sun MK, Lim C, Sen A, Khan T, Chirila FV, Alkon DL.

J Alzheimers Dis. 2017;58(2):521-535. doi: 10.3233/JAD-170161.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias